This review was designed to evaluate the progress in studies of the use of oral and topical antiretroviral (ARV) medication for primary HIV prevention.
INTRODUCTION
The use of oral antiretroviral (ARV) medications to prevent HIV transmission in at risk, HIV-infected individuals, has been demonstrated in several pivotal studies of preexposure prophylaxis (PrEP) [1] [2] [3] [4] [5] [6] , which complements HPTN 052, the first efficacy trial to demonstrate that early initiation of highly active ARV therapy decreased HIV transmission from HIV-infected persons to their uninfected partners [7] . The 96% reduction in HIV transmission seen in HPTN 052 was the most significant effect seen in any HIV prevention study, supporting the hypothesis that expanded and earlier HIV treatment as prevention (TasP) could substantially arrest the spread of HIV globally. However, since 2/3 of people living with HIV are not yet on treatment, ARV chemoprophylaxis may be able to play an important role in slowing epidemic spread, as more and more HIV-infected people initiate treatment.
To date, four PrEP efficacy trials testing oral tenofovir disoproxil fumarate (TDF) alone or in combination with emtricitabine (TDF/FTC) for prevention of HIV have been conducted in heterosexual men and women (Table 1) [1,2,3,6,5,8,9 && ,10], with three efficacy trials conducted in men and transgender women who have sex with men [1, 5, 6] and one in people who inject drugs [4, 11] (Table 1) . Several of these trials demonstrated PrEP efficacy, whereas others did not ( Fig. 1) [11] . All three oral PrEP studies in men and transgender women who have sex with men [1, 5, 6] , and a study of oral PrEP for injecting drug users [4] , demonstrated significant protection for those randomized to use TDF/FTC, as did two trials in African men and women [2, 3] , whereas three
INITIAL STUDIES DEMONSTRATING PREEXPOSURE PROPHYLAXIS EFFICACY
The Partners PrEP Study recruited 4747 serodiscordant couples from Uganda and Kenya to evaluate the use of oral TDF and FTC/TDF as PrEP (Table 1) [2] . Seronegative partners were randomized to receive once-daily TDF, FTC/TDF, or placebo. During an interim analysis of the study, the independent data and safety monitoring board recommended the discontinuation of the placebo arm because of the study meeting the pre-established stopping guidelines for efficacy [2] . The study demonstrated that both oral TDF and FTC/TDF significantly reduced HIV incidence in the HIV-uninfected partner (TDF: 67% [95% confidence interval (CI): 44-81] and FTC/ TDF: 75% (95% CI: 55-87) [2] . The TDF2 study which was conducted in Botswana enrolled 1219 sexually active, HIV-negative men and women between the ages of 18-39 years [3] . Participants were randomized to receive either daily oral FTC/ TDF or placebo. This study also demonstrated a high level of PrEP efficacy of 62% (95% CI: 22À83). The Iniciativa Profilaxis Pre-Exposició n (iPrEX) study randomized 2,499 men and transgender women who had sex with men in the USA, Peru, Ecuador, Brazil, Thailand, and South Africa to use either daily TDF/FTC or a matched placebo, and found overall efficacy for HIV prevention to be 44% (95% CI: . The Bangkok TDF PrEP study enrolled 2.413 Thai injecting drug users, who were randomized to use daily TDF versus placebo, and efficacy was 49% (95% CI: 10-72%). The PROUD study enrolled 400 British MSM who accessed services at genitourinary medicine clinics around the UK, who were randomized to initiate FTC/TDF PrEP right away, or to be provided with counseling and condoms while on a waiting list and found an 86% reduction in HIV incidence among those who had early access to PrEP (3 versus 19 infections) [5] . The Intervention Préventive de l'Exposition aux Risques avec et pour les hommes Gays (iPERGAY) study evaluated eventdriven PrEP in 545 French and Canadian MSM, who were randomized to receive FTC/TDF or matched placebo medication and asked to take two pills between 24 and 2 h prior to condomless anal intercourse, and then to take a pill a day for the next 2 days [6] . Those randomized to the active medication arm experienced an 86% reduction in HIV risk (2 versus 14 infections).
Preexposure Prophylaxis Trial for HIV Prevention among African Women (FEM-PrEP) was a randomized placebo-controlled trial which evaluated the safety and effectiveness of a once-daily oral dose of FTC/TDF in preventing HIV infection among high-risk women in Kenya, South Africa, and Tanzania [8] . Oral FTC/TDF efficacy was reported to be 6% (95% CI: À52À41%). The recently completed Vaginal and Oral Interventions to Control the Epidemic study was a multisite, randomized placebocontrolled trial involving 5029 HIV-negative women from South Africa, Uganda, and Zimbabwe who were randomized to receive either oral TDF, oral FTC/TDF, or vaginal tenofovir gel [9 && ]. The VOICE trial reported efficacy outcomes of 15% (95% CI: À20À40) for vaginal tenofovir gel, À49% (95% CI: À129-3) for oral TDF and À4% (95% CI: À49-27) for oral FTC/TDF.
The major reason for the diverse range of efficacy estimates in the different studies of PrEP is because of the variable levels of medication adherence seen in the different populations (Table 1) [11] . In the Partners PrEP study, ARV medication was detected in blood specimens of participants assigned to use active medication about 80% of the time, whereas medication detection was seen in less than 30% of samples tested in the VOICE and FEM-PREP studies ( Fig. 1 ) [13] . A third study of peri-coital use of tenofovir gel in South African women (FACTS 001) also failed to demonstrate efficacy, largely because of suboptimal adherence to product use. [12] 
FROM PROOF OF EFFICACY TO EFFECTIVENESS STUDIES
Although HPTN 052 demonstrated the efficacy of early treatment as prevention, questions remained regarding the robustness of the findings in realworld settings [14] . Several community-randomized clinical trials are underway to understand the impact of TasP on a population level [15] . The ANRS
KEY POINTS
Suppression of HIV replication with the use of highly active ARV therapy decreases HIV transmission efficacy substantially.
The use of PrEP can significantly decrease the risk of HIV infection among at risk uninfected people, but nonadherence can mitigate any potential benefit.
Currently, daily oral tenofovir-emtricitabine is the only medication that has been approved by some regulatory bodies for use as PrEP, but ongoing research is assessing the potential of other drugs, dosing regimens, and delivery mechanisms (for example, parenteral administration) for chemoprophylaxis.
12249 TasP is a two-arm cluster-randomized trial which is being conducted in rural Kwazulu Natal, South Africa. [16] . Following home-based rapid HIV testing, individuals diagnosed with HIV in the intervention group are being offered immediate antiretroviral treatment (ART), regardless of their CD4 cell count. In the comparison group, treatment was offered according to the South African treatment guidelines at the time ( 350 cells ml) [16] . Results from the first phase of the trial showed that the repeat (three 6-monthly rounds) home-based HIV testing strategy used was acceptable and feasible in the communities [16] . It is expected that results showing the impact of TasP on the HIV incidence in this population will be available by the end of 2016 [17] . Other community-randomized TasP studies include HPTN 071 (PoPART) being conducted in South Africa and Zambia, SEARCH being conducted in Kenya and Uganda, and the Machudi Project being conducted in Botswana. Each of these studies is comparing not only the impact of early initiation of highly active antiretroviral therapy (HAART) on community viral load, but are also evaluating different components, including incentivized homebased testing, enhanced couples counseling, and the impact of adding other health screening practices (for example, measuring blood pressure and blood glucose) on the uptake of, and adherence to, HAART, and the ultimate impact in decreasing HIV incidence.
Several of the PrEP efficacy trials have been followed by open label extension studies to assess the effectiveness of PrEP in the real world. Of the 1219 former TDF2 participants, 229 participants subsequently were located and initiated daily TDF/FTC PrEP [18] . Participants who elected to use open label FTC/TDF perceived themselves, or their partners to be at higher risk for HIV compared with those participants who did not start PrEP. The Partners Demonstration Project has evaluated the delivery of early ART initiation and PrEP for prevention of HIV transmission in high-risk heterosexual serodiscordant couples in Uganda and Kenya (http:// depts.washington.edu/uwicrc/research/studies/demo. html) [10] . ART has been provided to the HIV-infected partner in accordance with the national treatment guidelines. The HIV-uninfected partner was offered PrEP immediately, with the option to discontinue once the HIV-infected partner was virologically suppressed. The study found exceedingly low rates of HIV transmission compared with historical controls (only two infections after more than a thousand person-years of follow-up), although a minority of the participants reported suboptimal adherence [19] . The iPrEX Open Label Extension Study enrolled 1603 HIV-uninfected participants from the original iPrEX study as well as participants from the original CDC TDF safety study and the ATN 082 study of young MSM in Chicago, of whom 1225 (76%) received PrEP [20] . Uptake was higher among those reporting condomless receptive anal intercourse [416/519 (81%) versus 809/1084 (75%), P ¼ 0.003] and having serological evidence of herpes [612/791 (77%) versus 613/812 (75%) P ¼ 0.03]. Of those who decided to continue PrEP, HIV incidence was 1.8 infections per 100 person-years, compared with 2.6 infections per 100 person-years in those who concurrently did not choose PrEP [hazard ration (HR) 0.51, 95% CI 0.26-1.01, adjusted for sexual behaviors], and 3.9 infections per 100 person-years in the placebo group of the previous randomized phase (HR 0.49, 95% CI 0.31-0.77). Among those receiving PrEP, HIV incidence was 4.7 infections per 100 person-years if drug was not detected in dried blood spots, 2.3 infections per 100 person-years if drug concentrations suggested the use of fewer than two tablets per week, 0.6 per 100 person-years for the use of two to three tablets per week, and 0.0 per 100 person-years for the use of four or more tablets per week (P < 0Á0001). PrEP drug concentrations were higher among people of older age, with more schooling, who reported noncondom receptive anal intercourse, who had more sexual partners, and who had a history of syphilis or herpes. A subsequent demonstration project that tracked the uptake of daily oral TDF/FTC for PrEP among MSM and transgender women in San Francisco, Miami and Washington, DC [21
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& ] found high levels of medication in blood specimens from participants, particularly those from San Francisco.
DAILY ORAL THERAPY: DELIVERY AND ACCESS ISSUES
Both TasP and PrEp should be delivered as part of a comprehensive HIV prevention package consisting of HIV counseling and testing, diagnosis and treatment of sexually transmitted infections (STIs), HIV/ AIDs and sexual health education, promotion of male and female condom use, and behavioral interventions [23 && ]. Numerous questions remain unanswered regarding the most optimal settings to deliver PrEP, suitable prescribers for PrEP, and effective models for monitoring PrEP use and safety and providing adherence and risk behavior counseling. Potential settings for PrEP delivery include public health and STI clinics, family planning services, private practice, HIV counseling and testing (HCT) centers, ARV clinics, and community-based clinics [24, 25] . Clinical settings may be the most practical locations for delivery of PrEP given that PrEP users would require frequent HIV testing, clinical evaluations, and long-term clinical monitoring [25] . Many demonstration projects are currently investigating various models of PrEP delivery in clinical settings. A PrEP demonstration project conducted in three different settings in San Francisco recently reported that the integration of PrEP into busy clinical settings is feasible [21 && ].
MEDICATION ADHERENCE
Adherence to PrEP was strongly correlated to the level of HIV protection in the trials that demonstrated efficacy [1] [2] [3] [4] 26] . It is thus imperative to monitor adherence closely during PrEP use. PrEP trials conducted to date have demonstrated that adherence measured using participant self-report and pill counts does not correlate with actual adherence measured by plasma drug levels [27, 28] . Given that self-report and pill counts are not reliable measures of adherence, real-time monitoring of plasma drug levels should be considered in the future PrEP trials to ensure that participants are really using the study intervention.
An adherence substudy was initiated within the Partners PrEP trial. This substudy aimed to objectively measure and support adherence at three of the Ugandan study sites [29 && ]. PrEP adherence was measured using unannounced home-based pill counts and electronic pill bottle monitoring. Additional intensified adherence counseling sessions were provided to participants whose adherence had fallen below 80%. Adherence increased to at least 80% in 92% of participants who received additional counseling intervention sessions [29 && ]. Qualitative research studies exploring issues around product adherence, acceptability, and risk perceptions will be instrumental in understanding the determinants of oral PrEP use. Findings from these studies may inform the development of new multilevel strategies that provide long-term support for achieving and maintaining optimal adherence in future PrEP trials and demonstration projects. VOICE D, an ancillary study, investigated the contextual and trial-specific issues influencing actual and reported product use and sexual behaviors during women's participation in VOICE [30] .
PREEXPOSURE PROPHYLAXIS AND DRUG RESISTANCE
One of the major concerns of PrEP use is the risk of selection and transmission of drug resistance among individuals who have undiagnosed baseline HIV infection, or who become infected while taking PrEP [31,32 && ]. Suboptimal adherence in individuals on ART also increases the risk of developing drug resistance. Considering that TDF and FTC are commonly used for the treatment of HIV, a major disadvantage of using these drugs as PrEP is the potential risk for selecting HIV drug resistance-associated mutations [27] . This may also compromise the future use of these ARVs for treatment of HIV infections [33] . Individuals undergo regular HIV testing in clinical trials and study product is discontinued immediately when seroconversion occurs, reducing the potential for selection of drug resistance [34, 35] . Thus far, there have been few reports of drug resistance in the PrEP trials conducted to date [35] . These reported cases of resistance were mainly related to undiagnosed baseline HIV infection when initially enrolled into the study [36] . Strategies to monitor HIV seroconversion, such as frequent HIV testing, using sensitive point-of-care assays that detect viral RNA or p24 antigen, to exclude acute HIV infection [32 && ], should be in place for individuals using PrEP in clinical settings in order to reduce the risk of drug resistance.
SAFETY OF PREEXPOSURE PROPHYLAXIS USE
Overall, TDF has a good safety profile but may cause gastrointestinal and renal side-effects, reduce bone density, and is associated with hepatic flares in hepatitis B-infected individuals when the use is withdrawn [24, 36] . The safety profile of FTC/TDF is comparable to that of TDF. Gastrointestinal sideeffects, such as nausea and vomiting, which generally occur over the first 1-2 months of FTC/TDF use, are the most common side-effects reported [26] . Participants randomized to the FTC/TDF group in FEM-PrEP and the TDF 2 study experienced higher rates of nausea and vomiting compared with those in the placebo group [3, 8] . Drug discontinuation because of hepatic and renal abnormalities (4.7%) was higher in the FTC/TDF group in FEM-PrEP [8] . In the TDF 2 study, participants who received FTC/TDF had a significant decline in bone mineral density compared with those who received placebo [3] . Long-term side-effects of oral TDF and FTC/TDF use in uninfected individuals have not been established as yet. Therefore, long-term safety issues, such as renal and bone toxicities, must be monitored in individuals taking these drugs [27] .
BEHAVIORAL DISINHIBITION/RISK COMPENSATION
Behavioral disinhibition leading to increased risky sexual behavior [37] has been raised as a concern with the use of PrEP, TasP, and other biomedical interventions. No evidence of risk compensation or decreased condom use was observed in the completed PrEP trials [2, 3, 8, 20] . Interestingly, the Partners PrEP study reported that condom use increased during the study follow-up period [2] . Given that current PrEP strategies are not completely effective [33] , and are not protective against other sexually transmitted infections [30, 36] , adequate behavioral change interventions should also be implemented to ensure that risk compensation does not occur in PrEP users. Individuals using PrEP should be provided with intensive ongoing education and counseling emphasizing the importance of condom use and safe sexual behavior [37] .
HIV TESTING AND LINKAGE TO CARE
It is vital that systems supporting regular HIV counseling, testing, and linkage to care are set up to enable effective implementation of both the TasP and PrEP strategies in real-world settings. Increasing, HIV testing rates in at-risk populations will be instrumental in scale-up of these interventions. Typical models for HCT in low-income and middle-income countries are facility-based [37] . In order to increase HIV testing rates other approaches such as expand workplace HCT, mobile HCT, and home-based HCT must be considered [38 && ]. As demonstrated by the Africa Center ANRS 12249 TasP trial [16] , the home-based HCT model is a suitable and effective and feasible strategy to implement at the population-level to increase HIV testing rates. Regular HIV testing will enable the identification of HIV-infected individuals requiring treatment and care; and HIV-uninfected, at-risk individuals who may be referred for PrEP. A major challenge for TasP and PrEP to become optimally effective public health strategies is the need for efficient referral and linkage of newly diagnosed HIV-infected and high-risk seronegative individuals to access care and treatment [38 && ,39] . These interventions require long-term monitoring to ensure retention in care for those individuals who initiate ART for treatment and prevention.
CONCLUSION
Over the past 5 years, the use of ARVs to prevent HIV transmission and acquisition has been demonstrated to be efficacious in a wide range of populations. However, because of the need for continued medication adherence and concerns about potential behavioral disinhibition and longer-term medication side-effects, demonstration projects to understand the longer term intended and unintended consequences of TasP and PrEP are underway. Other studies are being conducted to evaluate whether different PrEP drugs, delivery systems (for example, gels, rings, and injections) or less than daily use regimens may offer advantages over daily use of oral TDF/FTC for PrEP.
